Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Neil Beeharry et al.|Journal of Hematology & Oncology|2018Cited by 56
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Ilaria Iacobucci et al.|Oncotarget|2016Cited by 42
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsStefania Trino, Giovanni Martinelli, Ilaria Iacobucci et al.|Oncotarget|2016Cited by 35
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaIlaria Iacobucci, Giovanni Martinelli, Loredana Elia et al.|Journal of Hematology & Oncology|2015Cited by 28
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing PrognosisIlaria Iacobucci, Giovanni Martinelli, Anna Ferrari et al.|Blood|2013Cited by 3